Mendus Ab Stock Fundamentals
| IMMU Stock | SEK 8.15 0.03 0.37% |
Mendus AB fundamentals help investors to digest information that contributes to Mendus AB's financial success or failures. It also enables traders to predict the movement of Mendus Stock. The fundamental analysis module provides a way to measure Mendus AB's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mendus AB stock.
Mendus |
Mendus AB Company Operating Margin Analysis
Mendus AB's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Mendus AB Operating Margin | (69.15) % |
Most of Mendus AB's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mendus AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Mendus AB has an Operating Margin of -69.1471%. This is 97.11% higher than that of the Healthcare sector and 38.3% lower than that of the Biotechnology industry. The operating margin for all Sweden stocks is notably higher than that of the company.
Mendus AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mendus AB's current stock value. Our valuation model uses many indicators to compare Mendus AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mendus AB competition to find correlations between indicators driving Mendus AB's intrinsic value. More Info.Mendus AB is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mendus AB's earnings, one of the primary drivers of an investment's value.Mendus Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mendus AB's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mendus AB could also be used in its relative valuation, which is a method of valuing Mendus AB by comparing valuation metrics of similar companies.Mendus AB is currently under evaluation in operating margin category among its peers.
Mendus Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (69.15) % | |||
| Current Valuation | 607.17 M | |||
| Shares Outstanding | 199.4 M | |||
| Shares Owned By Insiders | 57.54 % | |||
| Shares Owned By Institutions | 11.78 % | |||
| Price To Earning | (4.53) X | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 354.29 X | |||
| Gross Profit | 6 K | |||
| EBITDA | (128.28 M) | |||
| Net Income | (130.1 M) | |||
| Cash And Equivalents | 155.31 M | |||
| Cash Per Share | 3.94 X | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 14.67 X | |||
| Book Value Per Share | 2.81 X | |||
| Cash Flow From Operations | (138.03 M) | |||
| Earnings Per Share | (0.63) X | |||
| Target Price | 6.75 | |||
| Number Of Employees | 31 | |||
| Beta | 1.04 | |||
| Market Capitalization | 427.98 M | |||
| Total Asset | 720.98 M | |||
| Retained Earnings | (100 M) | |||
| Working Capital | 36 M | |||
| Current Asset | 45 M | |||
| Current Liabilities | 9 M | |||
| Net Asset | 720.98 M |
About Mendus AB Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mendus AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mendus AB using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mendus AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.